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Brain microvascular endothelial cells (BMECs) are
an essential component of the blood-brain barrier
(BBB) that shields the brain against toxins and im-
mune cells. While BBB dysfunction exists in neuro-
logical disorders, including Huntington’s disease
(HD), it is not known if BMECs themselves are func-
tionally compromised to promote BBB dysfunction.
Further, the underlying mechanisms of BBB
dysfunction remain elusive given limitations with
mouse models and post-mortem tissue to identify
primary deficits. We undertook a transcriptome
and functional analysis of human induced pluripo-
tent stem cell (iPSC)-derived BMECs (iBMEC) from
HD patients or unaffected controls. We demonstrate
that HD iBMECs have intrinsic abnormalities in
angiogenesis and barrier properties, as well as in
signaling pathways governing these processes.
Thus, our findings provide an iPSC-derived BBB
model for a neurodegenerative disease and demon-
strate autonomous neurovascular deficits that mayCell
This is an open access article under the CC BY-Nunderlie HD pathology with implications for thera-
peutics and drug delivery.INTRODUCTION
Huntington’s disease (HD) is a devastating neurodegenerative
disorder caused by a CAG repeat expansion in the Huntingtin
(HTT) gene (The Huntington’s Disease Collaborative Research
Group, 1993) encoding an expanded polyglutamine (polyQ)
track in the Huntingtin (HTT) protein. A broad range of cellular
functions are impacted by mutant HTT (mHTT) expression (Mu-
noz-Sanjuan and Bates, 2011; Ross and Tabrizi, 2011). Symp-
toms include progressive cognitive, psychiatric and motor
impairment, and degeneration of striatal neurons and atrophy
of cortical neurons are hallmark neuropathological features
(Walker, 2007).
Impairment of the neurovascular unit (NVU) and blood-brain
barrier (BBB) has emerged as a feature of various neurodegener-
ative diseases, including HD (Drouin-Ouellet et al., 2015; Hua
et al., 2014; Lin et al., 2013). The NVU is composed of both
neuronal and non-neuronal cells (astrocytes) that regulate cen-
tral nervous system (CNS) homeostasis through interactions
with blood vessels (brain microvascular endothelial cells,Reports 19, 1365–1377, May 16, 2017 ª 2017 The Author(s). 1365
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A B
C
D E F
G
Figure 1. iBMECs from Healthy Control Patients Stain for BBB Markers, Show Functional Barrier Properties, and Provide Insight into Novel
Regulators of BBB Genes
(A) Diagram of the human BBB. Paracellular transport is prevented by TJs formed by CLAUDINS (CLDN; blue), OCCLUDIN (OCLN; red), and ZONAOCCLUDENS
(ZO; purple oval). The low levels of transcytosis are controlled by a small number of caveolae expressing CAVEOLIN-1 (orange circles and light blue). Lastly, the
transport and efflux of molecules are regulated by solute carriers, ATP-binding cassette genes, and other ion channels.
(B) Representative images for control iBMEC stained for PECAM-1 (CD31) (28Q), GLUT-1 (SLC2A1) (33Q), CLDN-5 (28Q), OCLN (33Q), and ZO-1 (33Q). The scale
bars represent 100 mm.
(C) Flow cytometry quantification of % CD31+ (594) and GLUT1+ (488) double positive control and HD cells. The bar graph shows greater than 90% pure
populations of iBMECs and no statistical difference between each sample using a one-way ANOVA [n = 3 (28Q), 5 (33Q), 7 (66Q), 5 (71Q), and 7 (109Q),
independent experiments/differentiations with a minimum of two technical replicates). The dot plot is shown for 33Q and 66Q iBMECs unstained, FMO, and fully
stained cells.
(legend continued on next page)
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BMECs, pericytes). BMECs are the main component of the NVU
that restricts paracellular and transcellular entry into the CNS via
tight junctions (TJs), a limited number of caveolae, and selective
transporters (Figure 1A) (Zhao et al., 2015). Chronic mHTT
expression alters the neurovasculature by increasing cerebral
blood volume, small vessel density, and BBB permeability in ro-
dentmodels of HD and patient tissue (Drouin-Ouellet et al., 2015;
Franciosi et al., 2012; Hsiao et al., 2015; Hua et al., 2014; Lin
et al., 2013). These changes were initially thought to originate
from neuronal deficits leading to secondary effects on the
NVU; however, recent studies have highlighted a dependency
on HD astrocytes for BBB pathology (Hsiao et al., 2015). Yet, it
is not known whether BMECs manifest cell-autonomous deficits
induced by mHTT expression, thereby potentially contributing to
observed HD pathology, or if BBB dysfunction is secondary to
neurodegeneration.
The development of iPSCs (Takahashi et al., 2007; Yu et al.,
2007) and efficient protocols to generate BMECs (Lippmann
et al., 2014) provide an opportunity to investigate the primary ef-
fects of neurodegenerative disease mutations on BMECs and
their contribution to disease pathogenesis. To address whether
BMECs have intrinsic deficits in HD, we generated human
iPSC-derived BMECs (iBMECs) from either unaffected or HD
subjects and performed functional assays and RNA-sequencing.
Through transcriptome analysis, we identify a set of novel BMEC
genes that could impact normal and diseased BBB function. This
analysis, coupled with assays that measure angiogenesis and
barrier function, suggest that HD iBMECs have increased angio-
genic potential and impaired barrier function through defects in
signaling pathways governing these processes. The transcrip-
tome analysis suggests that mutant HTT protein regulates
epigenetic marks that control changes in BMEC-specific gene
expression, including those crucial for angiogenesis and barrier
formation. Moreover, it suggests a potential mechanism that
links mHTT with BBB dysfunction in HD, which is validated
through a targeted intervention to ameliorate the angiogenic
deficit. This HD iBMEC model represents an important resource
to evaluate therapeutics that might restore normal BBB function
and to assess drug delivery to the CNS.
RESULTS
Generation and Transcriptome Analysis of Unaffected
Control Human iPSC-Derived BMECs
To define the transcriptome and functional characteristics of
healthy iBMEC, iPSCs from unaffected individuals were differen-
tiated into BMECs as described (Lippmann et al., 2014). There(D) Scatterplot of TEER values from control iBMECs (blue, 33Q and 28Q) and co
shown as average between two control iPSC lines (28Q and 33Q) and one iNPC co
statistical difference in TEER values between two control iBMEC samples, but a
[(n) = 14 (33QBMEC), 16 (28QBMEC), 3 (NPCs, adjusted p values = 1.943 104 (2
independent experiments/differentiations per sample; ANOVA with Bonferroni po
(E) List of uniquely expressed CLDNs found in RNA-seq data from control iBMEC
(F) A Venn diagram of shared SLC- and ABC- transporters between control iBM
(G) Selected results from motif analysis on all SLC- and ABC- transporter genes
calculated enrichment of that motif in random sequences with similar GC conten
For all of the error bars (mean ± SEM).were two control iPSC lines from unaffected individuals having
33 or 28 CAG repeats in the HTT gene (CS83iCTR33n1, desig-
nated 33Qn1 [33Q] and CS14iCTR28n6, designated 28Qn6
[28Q]) that were differentiated (HD iPSC Consortium, 2017;
TablesS1andS2). Each lineexpressedmarkersofhumanBMECs
including PECAM1 (CD31) and GLUT1 (SLC2A1) and formed
linear TJ strands characterized by co-localization of CLAUDIN-5
(CLDN5), OCCLUDIN (OCLN), and TIGHT JUNCTIONPROTEIN 1
(TJP1 [ZO1]) (Figure 1B). Flowcytometry analysis of the fraction of
CD31+ and GLUT1+ double positive cells after differentiation and
subculture showed that greater than 90% of the cell population
were BMECs (Figure 1C). Functionally, iBMECs exhibited a high
transendothelial electrical resistance (TEER) over several days,
characteristic of normal BMECs (Figure 1D). TEER values peaked
between 48 and 72 hr post-subculture, but remained higher than
300Uxcm2 for over 120 hr (Figure 1D). In contrast, iPSC-derived
neural precursor cells (iNPCs) from the same patient (33Q)
showed no TEER over 120 hr (Figure 1D) (n = 3, 33Q-iNPC
adjusted p values = 1.94 3 104 [24 hr], 1.44 3 103 [48 hr],
2.74 3 104 [72 hr], and 9.37 3 103 [96 hr], n.s. [120 hr], two-
way ANOVA and Bonferroni post hoc correction].
iBMECs were analyzed for expression of BBB-specific genes
by comparing their transcriptome (RNA-sequencing [seq]) to ex-
isting gene expression data collected from either primary human
BMECs isolated by laser capture microdissection and purifica-
tion or two immortalized BMEC lines (hCMEC/D3 and HBEC-
5i) (datasets are listed in Table S3 and described in Huntley
et al., 2014; Zhang et al., 2014). Due to difficulties in comparing
RNA-seq and microarray data across studies (SEQC/MAQC-III
Consortium, 2014), we focused on a binary approach by
comparing whether a BBB-specific gene was present or absent.
The control iBMEC data were mined for genes essential for
BBB function, including junctional, caveolar, and transporter
proteins. CLDNs are the principal constituents of TJs that form
a paracellular barrier. Although CLDN-3 and -5 are the main
TJs, we found additional CLDN genes (e.g., CLDN-1, -4, -7,
-11, -12, -18, -19, -20, and -23) expressed in our dataset. Some
CLDN genes (e.g., CLDN-2, -6, -8, -9, -10, -15, and -16) and
ZO-3 were uniquely expressed in iBMECs (Figure 1E), whereas
OCLN and all three JAM proteins (F11R, JAM-2, and -3) were ex-
pressed in all datasets (Figure 1E). A second key constituent of
the BBB is transporter proteins, including solute carrier trans-
porters (SLC) and active efflux transporters. Profiling of 359 hu-
man SLC and 49 ATP-binding cassette (ABC) genes showed
that 286 transporter-encoding genes were unique to human
BMECs and 59 non-unique genes were expressed 2-fold higher
in BMECs than cortex (Geier et al., 2013). Our RNA-seq datantrol iNPCs (red, 33Q) lines over 120 hr. The TEER values for the iBMECs are
ntrol line over three individual readings taken from triplicate wells. There was no
significant difference was seen between two control iBMECs with the iNPCs
4 hr), 1.443 103 (48 hr), 2.743 104 (72 hr), and 9.373 103 (96 h), n.s. (120 hr)
st hoc correction].
s.
ECs data and previously published BMEC transcriptomic data.
expressed in control iBMECs. p values represent the likelihood of finding the
t. See also Tables S1–S5. # (*p < 0.05; **p < 0.01; and ***p < 0.001).
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identified 173 genes that overlapped with 241 previously identi-
fied genes of the combined SLC and ABC families and revealed
an additional 56 novel SLC and ABC genes (Figure 1F; Table
S4). These findings (173 of the 241 transporter genes) showed
a high statistical significance of overlap (p < of 0.000), validating
the use of iBMECs as a model.
To identify potentially novel upstream transcription factors
that regulate SLC and ABC genes, we used transcription factor
motif analysis (Figure 1G; Table S5). THEME software was
used to identify enriched upstream regions of every motif in the
TRANSFAC and SELEX databases (Jolma et al., 2013; Wing-
ender et al., 1996). The top motif identified the transcription fac-
tor NRF-1 (p = 6.75 3 1012), that regulates not only mitochon-
drial biogenesis, but also HIF1a during hypoxia (Wang et al.,
2016). The HIF-1motif, where HIF-1a binds in hypoxic conditions
to upregulate pro-angiogenic genes (Forsythe et al., 1996), was
also highly enriched (Figure 1G). Finally, ELK-1 and STAT-3 DNA
binding motifs were enriched suggesting that these transcription
factors may function in cooperation with HIF-1a in iBMECs to
promote angiogenesis (Chamorro-Jorganes et al., 2016; Chera-
nov et al., 2008). Thus, pro-angiogenic transcription factors func-
tion upstream of BBB-specific genes to coordinate angiogenesis
and barrier maturation in iBMECs.
HD iBMECs Have Functional Deficits in Angiogenesis
and Barrier Properties
We next differentiated HD patient-derived iPSCs into iBMECs
as above to determine whether the presence of mHTT
confers impairment in BMEC function. There were four human
HD iPSC lines with expanded repeats of 60Q, 66Q, 71Q,
and 109Q (CS21iHD60n8, CS04iHD66n4, CS81iHD71n3, and
CS09iHD109n1; Seong et al., 2010), representative of early
onset HD, that were differentiated into iBMECs (Lippmann
et al., 2014). No statistically significant differences in the per-
centage of HD iBMECs (CD31+/GLUT1+ cells; >90% pure popu-
lations; Figure 1C) compared to control iBMECs were observed
after differentiation. HTT protein levels were similar between
control and highly expanded repeat lines (HD iPSC Consortium,
2012; Mattis et al., 2015).
We first performed a wound-healing assay to assess the
angiogenic potential of iBMECs by measuring the distance that
cells travel toward a wound area. HD iBMECs showed increased
migration into the wound over a 6 hr time period compared to
control lines (Figures 2A and 2B) [adjusted p value = (66Q
4.69 3 104), (71Q 9.02 3 103); one-way ANOVA and Bonfer-
roni post hoc correction]. To determine whether this effect was
due to either increased migration or altered proliferation, we
quantified the number of proliferating iBMECs in both control
and HD lines and migration across a Transwell system with
increasing doses of VEGF in the bottom chamber. There was
no significant difference in the number of proliferating iBMECs
between any of the HD or control lines, but there was a marked
increase in HD iBMECmigration in the Transwell migration assay
(Figures 2C and 2D). Although each iBMEC line (control or HD)
showed a dose-dependent response to VEGF, HD iBMECs
had increased migration compared to control iBMECs even in
the absence of VEGF (Figure 2C) [adjusted p value = (66Q
2.22 3 102, 3.22 3 102, and 7.15 3 103), (71Q 2.83 31368 Cell Reports 19, 1365–1377, May 16, 2017102, 2.31 3 102, and 3.21 3 102), and (109Q 9.06 3 103,
4.67 3 104, and 8.85 3 105; two-way ANOVA and Bonferroni
post hoc correction]. There was no significant difference in the
number of apoptotic or dead cells among any of the control or
HD iBMECs with the exception of the highly expanded 109Q
line, which has a higher susceptibility to cell death (Figures 2E
and 2F) (adjusted p value = 109Q 1.99 3 102 and 5.26 3
104, ANOVA and Bonferroni post hoc). These findings demon-
strate that HD iBMECs have increased angiogenesis compared
to control iBMECs.
We next examined whether HD iBMECs displayed altered TJs
and paracellular barrier function. iBMECs did not show any
abnormalities in OCLN localization at cell junctions in control or
HD lines (Figure 3A); however, CLDN5 was localized both at
junctions and intracellularly in HD (66Q, 71Q, and 109Q), but
not control (28Q and 33Q) iBMECs (Figure 3A) [p value =
(7.76 3 103); Student’s t test]. Protein levels for either CLDN5
or OCLN were unchanged (Figure 3B; ANOVA with Dunnett’s
multiple comparison test). To examine BBB function, TEER
measurements were performed on HD and control iBMECs
over 96 hr. There was a significant decrease in maximal TEER
values in HD iBMECs at 72 hr compared to control lines particu-
larly in those with expanded repeats above 70Qs (e.g., 71Q
and 109Q) (Figure 3C) [adjusted p value = (60Q 4 3 102),
(66Q 1 3 103), (71Q 1 3 106), and (109Q 1 3 109); ANOVA
with Bonferroni post hoc correction]. Thus, some TJ proteins
and paracellular barrier function are altered in HD iBMECs.
A major function of the BBB is to prevent influx of harmful mol-
ecules into the brain (Zhao et al., 2015). AlteredMDR1 (ABCB1 or
P-GLYCOPROTEIN) transporter function has been reported in
HD (Kao et al., 2015), prompting us to examine whether this
transporter might be impaired in HD iBMECs. We performed a
puromycin survival assay that relies on the ability of BMECs to
extrude puromycin and survive via MDR1 for 48 hr (Perrie`re
et al., 2005). HD iBMECs were unable to survive the antibiotic
treatment, even at low levels of puromycin, compared to control
lines (Figure 3D) [adjusted p value = (60Q 9 3 103 and 1.05 3
103) and (109Q 1 3 102 and 1.08 3 102); two-way ANOVA
with Bonferroni post hoc correction]. The poor survival rate
correlated with increased polyQ length, suggesting that MDR1
has either low expression or aberrant function (Figure 3D). As
an independent assay for MDR1 function, we used flow cytom-
etry to quantify the uptake of Rhodamine 123 (R123), a dye trans-
ported by MDR1 (Miller et al., 1997). We also tested an iNPC line
from the same 33Q iPSC, since these cells do not express the
MDR1 gene and will take up the dye. An increase in R123 uptake
was observed in all HD samples, and the 33Q iNPC cells,
compared to control iBMECs (Figure 3E) [adjusted p value =
(66Q 1.23 3 102), (71Q 4.5 3 104), (109Q 1.96 3 106), and
(33Q-iNPC 5.58 3 107); one-way ANOVA with Bonferroni post
hoc correction], verifying that efflux function is reduced in HD
iBMECs. Additionally, treatment with the MDR1 inhibitor Cyclo-
sporine A for 1 hr prior to R123 exposure, inhibited the ability
of both control and HD iBMECs to efflux R123 (Figure S2). We
quantified MDR1 protein levels by flow cytometry to determine
if it was reduced, but surprisingly we found increased MDR1
levels in all HD lines (Figure 3F) [adjusted p value: 33Q (n = 4)
and 28Q (n = 8), 66Q (n = 6 and 4.59 3 105), 71Q (n = 3 and
A B C
D E F
Figure 2. HD iBMECs Show Increased Migration
(A) Wound-healing assay shows HD iBMECs have increased migration into wound. The images are 0 and 6 hr time points. The scale bars represent 200 mm.
(B) Plot shows change in area over time [(n) = 4 (all lines) independent experiments/differentiations; adjusted p value = (66Q 4.69 3 104) and (71Q 9.023 103)
with ANOVA and Bonferroni post hoc correction]. The lines used were 28Q, 33Q, 66Q, and 71Q.
(C) Transwell migration assay showing increased migration after 24 hr of HD compared to control iBMECs treated with 0, 50, or 100 ng/mL VEGF [(n = 3 (28Q), 3
(33Q), 3 (66Q), 2 (71Q), and 3 (109Q) independent experiment/differentiations with five images counted per growth replicate; adjusted p value = (66Q 2.223 102,
3.22 3 102, and 7.15 3 103), (71Q 2.83 3 102, 2.31 3 102, and 3.21 3 102), and (109Q 9.06 3 103, 4.67 3 104, and 8.85 3 105); two-way ANOVA and
Bonferroni post hoc correction].
(D) Quantification of proliferating cells in HD and control iBMECs by % Ki67 positive shows no statistical difference (n = 3 independent experiments/differen-
tiations with five images counted per two growth replicates each; one-way ANOVA).
(E and F) Quantification of relative number of dead (E) and apoptotic (F) cells in HD and control iBMECs by flow cytometry. Only 109Q HD iBMECs have a
significant increase in the number of apoptotic and dead cells [(n = 10 (28Q), 8 (33Q), 11 (66Q), 9 (71Q), and 8 (109Q) independent experiment/differentiations
comparing controls to each individual HD line (adjusted p value = 109Q 1.99 3 102 and 5.26 3 104); one-way ANOVA and Bonferroni post hoc correction].
# (*p < 0.05; **p < 0.01; and ***p < 0.001).
For all of the error bars (mean ± SEM).1.773 103), and 109Q (n = 3 and 2.893 106); one-way ANOVA
andBonferroni post hoc correction]. These findings demonstrate
altered MDR1 function in iBMECs carrying mHTT.
Endothelial Transcytosis Is Impaired in HD iBMECs
mHTT aggregates are primarily concentrated in endocytotic ves-
icles within CNS blood vessels of HD mice and patients (Drouin-
Ouellet et al., 2015). Increased fluorescently labeled albumin,
which enters the CNS by CAVEOLIN-1-mediated transcytosis,
is also found within the CNS of R6/2mice after intravenous injec-
tion (Drouin-Ouellet et al., 2015). We examined endothelial endo-
cytosis in control or HD iBMECs and 33Q iNPCs by measuring
the amount of fluorescently labeled albumin inside cells after a
1 hr treatment by flow cytometry. Each HD iBMEC line and the
iNPCs had increased albumin uptake compared to control
iBMECs (Figure 3G) [adjusted p value = (66Q 3.04 3 103),
(71Q 9.18 3 106), (109Q 1.01 3 108), and (33Q-iNPC 1.59 3
109); ANOVA with Bonferroni post hoc correction], suggesting
a higher rate of endocytosis. CAV-1 was also expressed at
higher levels in HD iBMECs compared to controls by flow cytom-etry (Figure 3H) [adjusted p value = (66Q 4 3 103), (71Q 5 3
103), (109Q 3 3 102); one-way ANOVA with Bonferroni post
hoc correction], suggesting an impaired transcytotic barrier in
HD iBMECs.
The Transcriptome of HD iBMECs Reveals Altered
Angiogenic and Barrier Gene Networks
The data above suggest that there are intrinsic deficits arising
in mHTT-expressing iBMECs. To determine whether mHTT im-
pacts BMEC gene expression leading to functional deficits,
RNA-seq was carried out on the HD iBMEC lines. Unsupervised
exploratory analysis (PCA) was used to examine differences be-
tween HD and control cells (Figure 4A). Although the highest vari-
ance is seen across all patient samples in principle component
(PC) #1, there is clear separation between control and HD sam-
ples across PC #2. A list of differentially expressed genes (DEGs)
between control and HD iBMECs was generated using DEseq2
and Partek Flow (Table S6). We then used the tissue specific
expression analysis (TSEA) tool (Xu et al., 2014) to explore tissue
specificity, which revealed that DEGs were mainly comprised ofCell Reports 19, 1365–1377, May 16, 2017 1369
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Figure 3. HD iBMECs Have Abnormal BBB Function
(A) Representative immunofluorescence micrographs for CLDN5 (33Q and 109Q) and OCLN (33Q and 71Q) in control and HD iBMECs (red arrows mark larger
puncta). The scale bars represent 10 mm. The bar graph shows relative CLDN5 intracellular puncta per cell. There is an increase in intracellular CLDN5 protein
inside HD cells, [(33Q n = 6), (28Q n = 3), (66Q n = 3), (71Q n = 6), and (109Q n = 3); p value = 7.763 103, Student’s t test]. There were at least three images at 1003
per experiment that were used.
(B) Western blots with bar graph quantitation of CLDN5 and OCLN levels with the LICOR system. The quantitation was normalized to b-ACTIN, and the bar graph
values are shown relative to 28Q line. No difference between any lines was found (ANOVA and Dunnett’s multiple comparison test).
(C) A bar graph of TEER values for control (black) and HD (gray) lines at 72 hr post subculture. The TEER is decreased in all HD iBMECs. The resistance values from
each triplicate measurement/well were averaged in each experiment containing three replicate wells per condition/sample [n and adjusted p value; (n) = 14 (33Q)
and 16 (28Q), (60Q n = 20 and 43 102), (66Q n = 11 and 13 103), (71Q n = 8 and 13 106), and (109Q n = 16 and 13 109); ANOVAwith Bonferroni correction].
(D) Histograms and bar graphs of the puromycin survival assay. The bar graph values are relative to untreated for each cell line (n = 3 independent experiments/
differentiations with triplicate wells for each condition and five images per well were counted comparing controls to each individual HD line [adjusted p value (60Q
9 3 103 and 1.05 3 103) and (109Q 1 3 102 and 1.08 3 102; ANOVA and Bonferroni post hoc correction].
(E) Flow cytometry quantification of Rhodamine 123 efflux/uptake in control and HD iBMECs. For the R123 uptake assay, controls were compared to each
individual HD line and a positive control iNPC [n and adjusted p value; (n) = 8 (33Q) and 17 (28Q), (66Q n = 13 and 1.233 102), (71Q n = 5 and 4.53 104), (109Q
n = 10 and 1.96 3 106), and (33Q-iNPCs n = 3 and 5.59 3 107); ANOVA and Bonferroni post hoc correction].
(F) Histograms shown for 33Q and 109Q and flow cytometry quantification of PGP protein levels showing an increase in HD iBMECs compared to controls [n and
adjusted p value; (n) = 4 (33Q) and 8 (28Q), (66Q n = 6 and 4.593 105), (71Q n = 3 and 1.773 103), and (109Q n= 3 and 2.893 106); ANOVAand Bonferroni post
hoc correction]. The histograms are shown for 28Q and 109Q.
(G) Flow cytometry quantification of CAV1 protein levels showing an increase in HD iBMECs [n and adjusted p value; (n) = 4 (33Q) and 11 (28Q), (66Q n = 8 and
43 103), (71Q n = 11 and 53 103), and (109Q n = 9 and 33 102); one-way ANOVA and Bonferroni post hoc correction]. The histograms are shown for 28Q and
66Q. There is reduced MDR1 function in HD iBMECs (R123) and less cell survival due to decreased efflux of puromycin.
(legend continued on next page)
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genes expressed in blood vessels (FDR = 1.048 3 1021 and
8.268 3 109, Fisher’s exact test with Benjamini-Hochberg
correction) (Figure S1A).
To identify specific pathways and regulators that control neu-
rovascular function in HD, Ingenuity Pathway Analysis (IPA) was
conducted on the DEGs. WNT/b-catenin, pro-angiogenic, and
leukocyte extravasation signaling, as well as cell junction or cav-
eolar-mediated transcytosis proteins, essential for BMEC barrier
function, were altered (Figure 4B). To determine changes in tran-
scription factor activity that might contribute to altered gene
expression and pathway activity, upstream regulator analysis
(IPA) and motif analysis were performed on HD iBMECs. WNT
(WNT3A), SHH (GLI2), Angiopoietin/Tie2 (ANGPT2), and TGFb1
signaling were predicted to be activated (Figure 4C). Motif
analysis on DEGs either expressed only, or upregulated, in HD
iBMECs, revealed that many DEGs were regulated by either
HIF-1a or ELK-1 (Table S7). This analysis supports the pro-
angiogenesis phenotype of HD iBMECs (Figures 2A–2C). To
determine if there is any correlation between the length of the
CAG-repeat with the predicted activation of the above path-
ways/regulators, we plotted the log2 normalized read count
data for each gene (downstream targets or critical pathway
members) and found a high correlation between CAG length
and DEGs expression/activation (Figure 4D).
To further uncover potential mechanisms contributing to
transcriptional dysregulation in HD iBMECs, we conducted GO
analysis, using Cytoscape (Shannon et al., 2003) and EnrichR
(Kuleshov et al., 2016). Biological process enrichment revealed
that genes promoting vascular sprouting and remodeling were
altered in HD iBMECs (Figures 5A and 5B). The majority of
DEGs in the HD iBMECs correspond to either cell adhesion
proteins, signaling receptors, or endothelial barrier regulators
(Figures S1B and S1C). Within the parent category of signaling,
components of the WNT/b-catenin pathway that regulate CNS
angiogenesis and BBBmaturation (Zhao et al., 2015) were upre-
gulated in HD iBMECs including ligands (WNT-3, -4, -6, -7B,
and -10A), effectors (TCF3 and TCF4), and downstream targets
(AXIN2 and APDCC1) (Figures 4B and 5B). Other pro-angiogenic
genes, such as NOTCH-3, -4, aV-INTEGRIN, and SMAD3 (Man-
cuso et al., 2008), were also upregulated (Figures 4B and 5B).
Surprisingly, ROBO-1 and -2 that downregulate VEGFR2 at the
beginning of EC differentiation (Mancuso et al., 2008) were upre-
gulated (Figures 4B and 5B). Collectively, these data indicate
that HD iBMECs are starting to mature by expressing the correct
gene sets required for maturation (e.g., ROBO-1 and 2); how-
ever, there is a delay compared to their control counterparts.
EnrichR analysis was used to identify possible epigenomic
modifications associated with altered gene expression in HD
iBMECs. SUZ12, a member of the polycomb repressive com-
plex 2 (PRC2), had the highest adjusted p value of all transcrip-
tion factors, suggesting a role for this complex in silencing
endothelial genes in HD iBMECs (Figure 5C) similar to neuronal(H) Histograms and bar graph of the albumin uptake assay show increased uptak
control iBMECs [n and adjusted p values; (n) = 12 (33Q) and 17 (28Q), (66Q n = 13
and (33Q-iNPCs n = 3 and 1.59 3 109); by one-way ANOVA and Bonferroni pos
***p < 0.001).
For all of the error bars (mean ± SEM). See also Figure S2.genes in HD neurons (Seong et al., 2010). This analysis
also implicates WNT signaling (TCF3), suggesting that the
TCF3/b-CATENIN complex may cooperate with PRC2 to dysre-
gulate HD iBMEC genes (Figure 5C). Consistent with the above
findings, ENCODE genome-wide histone modification analysis
identified H3K27me3 and H3K4me3 as marks present at regula-
tory sites on DEGs altered in HD iBMECs (Figure 5D). Since
several genes of the PRC2 complex and effectors of histone
methylation are downregulated in both HD iBMECs (Figure 5E)
and neurons, mHTT may promote dysfunction of multiple cell
types at the epigenomic level.
WNT/b-Catenin Pathway Is Activated in HumanHDBrain
Tissue and Its Inhibition Rescues Angiogenic Deficit
In Vitro
To validate some of the transcriptome findings from HD iBMECs
in human patient tissue, we performed immunohistochemistry
and western blotting on human cortical tissue obtained at au-
topsy from patients with early-grade HD and age-matched
non-neurological disease controls (New York Brain Bank; Table
S8). SinceWNT signaling is activated in HD iBMECs (Figures 4B,
5B, and 5C), we examined expression levels of SOX17, a tran-
scriptional target of WNT/b-catenin signaling in both mouse
and human BMECs (Lengfeld et al., 2017). SOX17 was ex-
pressed in blood vessels in HD cortex and was 2.5-fold higher
in HD brain compared to unaffected tissue (p < 0.01, two-way
Student’s t test) (Figures 5F and 5G).
To test whether our transcriptome analysis can identify
underlying mechanisms contributing to altered iBMEC function,
we performed thewound healing assay in the presence of a small
moleculeWNT inhibitor, XAV939. Treatment of 33Q iBMECswith
20 mM XAV939 had no effect on their ability to migrate; however,
XAV939 significantly reduced the migration of each HD iBMEC
line compared to vehicle treated cells, comparable to the control
33Q line [adjusted p value = (33Qv66Q 43 102), (33Qv71Q 23
106), (33Qv109Q 5 3 105), (66Qv66Q-XAV 5 3 103),
(71Qv71Q-XAV 1 3 104), and (109Qv109Q-XAV 2 3 103);
two-wayANOVAwithBonferroni post hoc correction] (Figure 6A).
These data demonstrate that inhibition of aberrant WNT
signaling in HD iBMECs rescues some of the angiogenic
defects and provides validation that aberrant WNT signaling
contributes to intrinsic deficits of HD iBMECs. Thus, the
transcriptome data provide predictive information about under-
lying pathogenic mechanisms that cause intrinsic functional
deficits in BMECs and potential targets for therapeutic interven-
tion in HD.
DISCUSSION
With the advent of iPSC technology and development of
disease relevant models through differentiation of patient
cells into cells of the NVU, we have the capability to determinee of albumin-A594 in HD iBMECs and positive control 33Q iNPCs compared to
and 3.043 103), (71Q n = 5 and 9.183 106), (109Q n = 10 and 1.013 108),
t hoc]. The histogram is shown for 28Q and 109Q. # (*p < 0.05; **p < 0.01; and
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A Figure 4. Exploratory, Pathway, and Motif Analysisof Transcriptomic Data from Control and HD
iBMECs Reveals mHTT Dysregulation of BBB Genes
and Related Pathways
(A) PCA of log2 normalized count data on global expression
demonstrates grouping within individual control or HD
samples and separation between both groups along PC#2.
(B) Hierarchical clustering of DEGs in signaling pathways
regulating BBB function using log2 normalized count data.
The heatmap shows expression values normalized to row
min (blue) and max (orange), with genes grouped by path-
ways indicated by the color bar. The FDR and fold change
are displayed for each gene.
(C) IPA upstream regulator analysis showing transcriptional
regulators predicted to be activated by calculation of acti-
vation Z scores. The p value was calculated by Fisher’s
exact test from expected and observed genes overlapping
with our DEG list and all genes regulated by each tran-
scription factor.
(D) Scatterplots of log2 normalized count data for NOTCH3,
TCF3, GLI2, and SMAD3, plotted by increasing CAG length,
with best fit line and R2 values displayed.
See also Tables S6 and S7.
1372 Cell Reports 19, 1365–1377, May 16, 2017
BA
C D E
F G
Figure 5. HD iBMECs and Patient Tissue Show Enrichment for Angiogenesis, WNT, and PRC2 Signaling and Histone Methylation
(A) Network mapping of BiNGO biological process analysis showing enrichment for genes that regulate WNT signaling, angiogenesis, and vascular development.
Node size = number of genes and node color = decreasing FDR blue to purple. All enrichment nodes have an adjusted p value < 0.05. Adjusted p values were
calculated based on overrepresentation of categories over a background sample using a hypergeometric test and adjusted using a Benjamini-Hochberg FDR.
(B) Gene network showing differentially expressed genes that are involved in angiogenesis and have a direct protein-protein interaction connection (edges). The
orange denotes genes upregulated and blue downregulated in HD.
(C) Combined ChEA and ENCODE analysis to determine transcription factors that regulate the DEGs. Adjusted p value by Fisher’s exact test and Benjamini-
Hochberg correction log (adjusted p value).
(D) Enrichment analysis of ENCODE histone modifications relevant to DEGs. Adjusted p value by Fisher’s exact test and Benjamini-Hochberg correction.
(E) PRC2 genes/effectors and histone methyltransferases that are dysregulated in HD iBMECs.
(F) Western blotting in human HD cortical tissue for the WNT/b-catenin transcriptional target SOX17. SOX17 is 2.5-fold higher in HD patient samples (p < 0.01,
Student’s t test).
(G) Immunohistochemistry for SOX17 in control or HD human cortex. The SOX17 (brown) is expressed in blood vessels (hematoxylin, blue). The scale bars
represent 20 mm. See also Table S8 and Figure S1. # (*p < 0.05; **p < 0.01; and ***p < 0.001).
For all of the error bars (mean ± SEM).
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Figure 6. WNT Inhibition Restores Angiogenic Deficits in HD iBMECs and Model of NVU Impairment in HD
(A) Wound-healing assay shows HD iBMECs treated with 20 mM XAV939 have decreased migration into the wound. The plot shows change in area overtime.
[(n) = 3 (all lines) independent experiments/differentiations and adjusted p value; (33Qv66Q 4.43 3 102), (33Qv71Q 2.27 3 106), (33Qv109Q 5.31 3 105),
(66Qv66Q-XAV 5.70 3 103), (71Qv71Q-XAV 1.34 3 104), and (109Qv109Q-XAV 2.96 3 103); two-way ANOVA and bonferroni post hoc].
(B) Model of EC barrier dysfunction in HD. Schematic diagram of NVU in HD and selected genes (yellow denotes genes upregulated and blue downregulated
in HD) that are changed in HD iBMECs and HD astrocytes. These genes may contribute to neuronal dysfunction and death. # (*p < 0.05; **p < 0.01; and
***p < 0.001).
For all of the error bars (mean ± SEM).cell-specific contributions to disease pathogenesis. Using
iPSCs to generate iBMECs from HD and unaffected control
subjects, we identified transcriptional and functional differ-1374 Cell Reports 19, 1365–1377, May 16, 2017ences in human HD iBMECs that demonstrate primary intrinsic
deficits in signaling pathways critical for CNS angiogenesis and
BBB function.
Studies suggest that constituents of the NVU are altered in
neurodegenerative diseases and may contribute to pathogen-
esis in cell-intrinsic or extrinsic ways including BBB dysfunction
(Zhao et al., 2015). Classically, it was assumed that there was no
overt BBB leakage in HD; however, recent data indicate vascular
abnormalities and BBB dysfunction (Drouin-Ouellet et al., 2015;
Hsiao et al., 2015). Our transcriptomic analysis of the HD versus
unaffected control iBMECs provides insights into the networks
uniquely altered that may underlie specific BBB functions. For
instance, WNT signaling that contributes to development of the
cerebrovascular network and BBB is altered in HD iBMECs.
The increase in WNT target gene (SOX17) in a small cohort
of early grade human HD cortical brain tissue and rescue of
angiogenic deficits in iBMECs by WNT inhibition are consistent
with dysregulation of WNT signaling in the endothelium. Thus,
mHTT affects WNT/b-catenin signaling activity and as a conse-
quence inhibits proper BMEC differentiation and maturation.
Dysfunctional WNT/b-catenin signaling has also been implicated
in BBB breakdown in Alzheimer’s disease (Liu et al., 2014; Riise
et al., 2015). Our findings consolidate the role of WNT signaling
as a key target leading to BBB dysfunction in neurodegenerative
diseases.
Since several dysregulated pathways (WNT, NOTCH, and
TGFb signaling) in HD iBMECs control angiogenesis and barrier-
genesis, this provides a potential mechanism to explain vascular
defects found in HD patients and mouse models. Prior studies
have attributed BBB deficits to increased astrocyte-mediated
VEGF signaling (Hsiao et al., 2015); however, our data suggest
that BMEC-intrinsic activation of pro-angiogenic signals likely
makes blood vessels more permeable, leading to neurovascular
dysfunction in HD. The delay in barrier formation may be due to
high levels of mHTT that uncouples angiogenesis with proper
expression of BBB-forming genes, leaving new small vessels
that increase in density as the disease progresses with defective
barrier properties unable to protect the CNS. This is consistent
with our findings of aberrant paracellular, transcellular, or trans-
porter barrier function in HD iBMECs. Pathway analysis of the
RNA-seq data showed that a significant number of affected
genes regulate both clathrin- and caveolin-mediated endocy-
tosis, which could lead to abnormal endo/transcytosis. These
include FABP4, DYNAMIN, and FILAMIN, which initiate vesicle
formation and scission, F-actin, several integrin subunits, and re-
ceptors that activate endocytosis (transferrin and low density li-
poprotein receptors) (Figure 4B). CAV-1-dependent endocytosis
is normally downregulated in mature BMECs (Zhao et al., 2015).
The presence of higher levels of transcytosis proteins (CAV-1)
suggests that HD iBMECs have not undergone full maturation,
but instead retain a more non-CNS endothelial phenotype.
Although MDR1 is increased in expression, the transporter is
non-functional. A recent study also showed increased MDR1
expression in both human HD post-mortem tissue and the R6/
2 mouse model of HD; however, there was increased functional
activity of the transporter in the HDmice (Kao et al., 2015). These
differences suggest the need to examine transporter function
in human CNS and the consequences for HD pathogenesis in
greater detail.
We previously identified a specific pattern of H3K4me3 occu-
pancy that marked genes dysregulated in HD neuronal cells inboth a mouse model of HD (Vashishtha et al., 2013) and cortex
of HD patients (Dong et al., 2015). Specific patterns of
H3K4me3 and H3K27me3 occupancy are also observed in HD
iPSC-derived neurons (HD iPSC Consortium, 2017), suggesting
that these histone modifications are ubiquitously disrupted in
multiple CNS cell types during HD progression. Therefore, epi-
genomic modulators may improve the function of multiple cells
in the HD brain. Moreover, our proof of concept studies targeting
WNT signaling in HD iBMECs suggest additional therapeutic
targets that could be used in combination with those targeting
neuronal deficits.
From a clinical perspective, therapeutic drug delivery into
the brain necessitates an understanding of the state of BBB
function in neurodegenerative diseases in order to develop
effective treatments. The network data and functional outcomes
reflecting these deficits in the HD iBMECs can help to identify the
most critical targets for therapeutic intervention and be a tool for
investigating fundamental biological and disease processes in
the NVU that affect the human cerebral vascular network. In a
complementary study (Vatine et al., 2017), a similar approach
was used to generate iBMECs from Allan-Herndon-Dudley syn-
drome patients and identify the underlying cause of pathology,
which had not been elucidated using animal models. The authors
find that reduced TH availability to neural cells underlies the
disease phenotype. The use of iBMECs to identify disease
mechanisms for two separate neurological disorders provides
confidence in the use of iPSC-derived BMEC models to under-
stand human disease. Finally, the iBMEC model may be used
to assess the CNS penetration of drugs under consideration
for CNS drug discovery programs and guide future treatments
for HD and other neurological disorder patients.
EXPERIMENTAL PROCEDURES
Generation and Characterization of Human Non-integrating iPSCs
Using Episomal Plasmids
HD and non-disease repeat iPSCs were generated and characterized as
described (Mattis et al., 2015) (and in Supplemental Information).
Maintenance and Differentiation of Human iPSC-Derived BMECs
and iNPCs
There were seven iPSC lines that were maintained on matrigel (BD Biosci-
ences) with mTESR (Stemcell Technologies). These cells were differentiated
into BMECs as described (Lippmann et al., 2014) and in Supplemental Infor-
mation. Control 33Q iPSC were differentiated into iNPCs as described (Ebert
et al., 2013).
Immunofluorescence
Cells were stained as described (Lippmann et al., 2014) and in Supplemental
Information. A list of antibodies and their use can be found in Supplemental
Experimental Procedures (Table S9).
Wound Healing, Migration, and Proliferation Assays
Wound healing: following differentiation, iBMECs were plated in collagen/
fibronectin-coated 12-well plates. After 24 hr, the cells reached 100% conflu-
ence and the initial scratch/wound was made. BMECs were either untreated,
treated with DMSO (vehicle), or 20 mM XAV939. There were two images/well
that were taken on an EVOS microscope at time 0 and 6 hr and six wells
were used for each experiment/differentiation. Transwell migration: BMECs
were plated in collagen IV/fibronectin-coated Transwells with 3.0 mM pores.
After 24 hr, cells were treated with VEGF (50 or 100 ng/mL) or vehicle. At
24 hr after VEGF treatment, the upper chamber of the Transwell was cleared
of cells using a cotton swab, the bottom well was fixed with 4% PFA. The
Transwell membrane was cut out and mounted on a glass slide with DAPI.
There were five DAPI images that were taken per well and three wells wereCell Reports 19, 1365–1377, May 16, 2017 1375
used for each experiment/differentiation. Proliferation: At 48 hr after subcul-
ture, iBMECs were fixed and stained for Ki67. There were five images that
were taken per chamber and two chambers were used for each experiment/
differentiation. ImageJ software was used to quantify the area of the wound,
the number of migrating cells, or Ki67 positive cells.
Transendothelial Electrical Resistance
TEER measurements were performed using an EVOM2 voltohmmeter (World
Precision Instruments). The resistance value (Uxcm2) of an empty filter coated
with collagen/fibronectin was subtracted from each measurement.
RNA-Seq and DE Statistics
Total RNA was isolated from cells. RNA with quality scores >9 were used for
the RNA-seq library generation. Paired-end reads were trimmed using a
base quality score threshold of >20 and aligned to hg19. Counts per gene
were quantified and analyzed with the R package DESeq2, or Partek Flow,
to identify differentially expressed genes. See Supplemental Experimental
Procedures and Table S6.
Exploratory, Pathway, and Motif Analysis of DEGs
Spearman’s ranked correlation was used for hierarchical clustering, and log2
transformed global expression values were used for PCA. QIAGEN’s IPA
(http://www.qiagen.com/ingenuity) and EnrichR (Kuleshov et al., 2016) were
used for pathway, network, and upstream regulator analysis. Cytoscape
was used to visualize GO analysis networks from BiNGO, Enrichment Map,
and ClueGO (Bindea et al., 2009; Maere et al., 2005; Merico et al., 2010; Shan-
non et al., 2003). THEME software was used for motif analysis. Also see Sup-
plemental Experimental Procedures for more detail.
Flow Cytometry, Efflux, and Transporter Assays
For uptake assays, cells were treated with either 10 mM rhodamine 123 (Life
Technologies) or 10 mM Albumin-Alexa594 (Life Technologies) and incubated
for 1 hr at 37C. Cells were dissociated into a single cell suspension, fixed us-
ing 4% PFA, and analyzed for molecule uptake by flow cytometry. Puromycin
efflux wasmeasured based on cell death after 48 hr treatment with either 0.5 or
1 mM puromycin. Flow cytometry was also used for protein quantification and
to determine the fraction of CD31+/GLUT1+ by dissociating cells 48 hr after
subculture, fixing, and staining with primary and secondary antibodies.
Apoptotic and dead cells were quantified by flow cytometry as described in
Life Technologies CellEvent Caspase-3/7 Green Flow Cytometry Assay Kit.
Human Tissue
Fresh frozen human cortical tissue was obtained from the New York Brain
Bank at Columbia University from three healthy controls and three individuals
with early HD (Table S8). Paraffin-embedded brain tissues from HD patients
and non-neurological disease controls were obtained from the tissue bank
at CUMC (D.A.; IRB protocol #AAAQ7343).
Western Blotting and Immunohistochemistry
Cell pellets from three independent experiments were lysed and western anal-
ysis performed with the LICOR quantitative fluorescence system as described
(Lengfeld et al., 2017), with antibodies against human CLDN-5, OCLN,
b-ACTIN (Invitrogen), and SOX17 (Abcam). Paraffin-embedded brain tissues
were used to assess SOX17 expression as described (Lengfeld et al., 2017).
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